amylin glp 1 dual agonist GLP-1 and in the Treatment of Obesity | Current Diabetes Reports Frontiers | Mechanisms of action

& Stephenson, J

With findings from numerous trials on glycemic, body weight and CV outcomes scheduled to be presented over the next 4 years, many more treatment options could be become available for providers in the near future, Davies said

Studies in mice suggest that GIP may potentiate the GLP-1-induced reduction of food intake and body weight by enhancing POMC expression and neuronal activation within distinct neuron populations in the hypothalamus (149)

For example, within the book of business for Employers Health, a leading group purchasing organization for pharmacy benefits, 60 percent of clients exclude obesity drugs, 25 percent cover them after prior authorization and the remainder allow access without any restrictions

GLP-1 has been proven to be a useful adjuvant therapy in type-2 diabetes mellitus, metabolic syndrome, and hyperglycemia

2023;doi:10.1056/NEJMoa2301972